Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
141
-
Total 13F shares, excl. options
-
72.4M
-
Shares change
-
-1.94M
-
Total reported value, excl. options
-
$458M
-
Value change
-
-$7.38M
-
Put/Call ratio
-
1.86
-
Number of buys
-
65
-
Number of sells
-
-56
-
Price
-
$6.32
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2019
171 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2019.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 141 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 72.4M shares
of 236M outstanding shares and own 30.66% of the company stock.
Largest 10 shareholders include BAUPOST GROUP LLC/MA (19.6M shares), Nantahala Capital Management, LLC (6.74M shares), ABRAMS CAPITAL MANAGEMENT, L.P. (5.66M shares), VANGUARD GROUP INC (5.52M shares), STATE STREET CORP (3.44M shares), Novo Holdings A/S (3.1M shares), Point72 Asset Management, L.P. (2.36M shares), Nuveen Asset Management, LLC (1.73M shares), GEODE CAPITAL MANAGEMENT, LLC (1.66M shares), and Clearbridge Investments, LLC (1.64M shares).
This table shows the top 141 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.